Eryxopan-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to manage gastrointestinal disorders characterized by acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with gastroparesis and dyspepsia. Pantoprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, effectively reducing gastric acidity and promoting mucosal healing in conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The synergistic action of these agents provides symptomatic relief and addresses both acid-related mucosal damage and motility disturbances. Eryxopan-DSR is indicated for patients requiring combined acid suppression and prokinetic therapy. It should be administered as prescribed, typically once daily before meals. Caution is advised in patients with cardiac arrhythmias, liver impairment, or hypersensitivity to the components. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Consultation with a healthcare professional is essential before initiating therapy to ensure appropriate use and monitoring.